The motor unit is a relay of four serially connected components — the anterior horn cell in the spinal cord, its peripheral nerve axon, the neuromuscular junction (NMJ) where the axon meets muscle, and the muscle fiber itself. A genetic lesion can strike at any one of these levels, and the central diagnostic insight is that where in the relay the defect lies dictates the clinical signature far more reliably than the specific gene does. This is why neuromuscular evaluation proceeds by localization first, gene second.

Why the pattern of weakness localizes the lesion. Proximal-predominant weakness without sensory loss points to muscle or anterior horn cell, because those large proximal muscles depend on the integrity of the fiber and its motor neuron, not on sensory feedback. Distal-predominant weakness with sensory loss points to peripheral nerve, because the longest axons — those reaching the feet — degenerate first (length-dependent dying-back) and they carry sensory as well as motor fibers. Fatigable weakness that worsens with sustained effort betrays the NMJ, where each successive nerve impulse depletes the safety margin of acetylcholine release.

Why creatine kinase (CK) is so informative. CK is an intracellular muscle enzyme; its serum level is essentially a readout of how fast muscle membranes are leaking. Massive elevations (>10× ULN) mean active fiber necrosis with membrane breakdown — the hallmark of the dystrophies. Normal CK in a weak patient effectively excludes a destructive myopathy and redirects attention to nerve or motor neuron, where the muscle fiber membrane stays intact.

Electrophysiology before genetics. Electromyography (EMG) and nerve conduction studies (NCS) confirm the localization and, crucially, distinguish demyelinating from axonal neuropathy by whether conduction velocity (myelin) or amplitude (axon number) is the abnormality. Pinning down the level converts a list of hundreds of candidate genes into a focused, testable differential.

Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are allelic X-linked recessive disorders caused by variants in the DMD gene (Xp21.2), which spans 2.4 Mb across 79 exons — the largest gene in the human genome. Its sheer size is itself clinically relevant: such an enormous target presents a large mutational surface, which is why dystrophinopathy is common and why roughly a third of cases arise from new mutations.

The mechanical role of dystrophin. Dystrophin is a long, spring-like rod protein that physically tethers the intracellular actin cytoskeleton to the dystrophin-associated protein complex (DAPC) spanning the sarcolemma, which in turn anchors to laminin in the extracellular matrix. This continuous mechanical chain distributes the force of each muscle contraction across the membrane rather than concentrating it. Dystrophin is therefore not an enzyme or a signaling molecule but a shock absorber — and this mechanical framing explains everything downstream.

Why loss of dystrophin destroys muscle. Without that shock absorber, the contracting sarcolemma tears under its own mechanical load. Each micro-tear lets extracellular calcium flood into the fiber, and the resulting calcium overload activates proteases, drives mitochondrial dysfunction and oxidative stress, and ultimately triggers fiber necrosis. Because contraction itself is the insult, the damage is relentless and use-dependent; over years the muscle's limited satellite-cell regenerative capacity is exhausted and dead fibers are replaced by fat and fibrous connective tissue — the substrate of progressive weakness and the calf pseudohypertrophy seen clinically. The massively elevated CK is simply this membrane leak made visible in the blood.

The reading-frame rule — why position predicts severity. The genetic logic of why one DMD deletion causes lethal Duchenne and another causes mild Becker was solved by Monaco et al. 1988: what matters is not how much of the gene is deleted but whether the deletion preserves the translational reading frame. Because the genetic code is read in non-overlapping triplets, a deletion whose length is not a multiple of three shifts every downstream codon, scrambling the message and generating a premature stop — no dystrophin at all, hence DMD. An in-frame deletion (a multiple of three) splices out an internal chunk but keeps the start and end of the reading frame aligned, so a shortened-but-coherent dystrophin is still made; it lacks part of the rod yet retains the actin- and DAPC-binding ends that do the mechanical work, hence the milder BMD. This is also the conceptual basis of exon-skipping therapy: deliberately removing an additional exon to restore the frame can convert a would-be DMD genotype into a BMD-like one.

Spinal muscular atrophy (SMA) has historically been the second most common fatal autosomal recessive disorder in children (after cystic fibrosis), though mortality has decreased dramatically with the advent of disease-modifying therapies (nusinersen, risdiplam, onasemnogene abeparvovec). The disease gene was identified by Lefebvre et al. 1995, and that single discovery set up the entire genetic architecture — and the therapeutic strategy — that follows.

The cause: a ubiquitous protein, a selectively vulnerable cell. SMA results from loss of the survival motor neuron protein (SMN) due to homozygous deletion of the SMN1 gene on 5q13. SMN is a housekeeping protein expressed in every cell, where it assembles the snRNP particles that carry out pre-mRNA splicing. The paradox of SMA is that a protein needed by all cells, when reduced, kills almost exclusively the lower motor neurons of the anterior horn. The leading explanation is that these very large, metabolically demanding neurons — with axons up to a meter long — have the least tolerance for a low SMN supply, so they are the first to fall below the threshold required for survival.

The SMN2 modifier: a near-twin that almost works. Humans uniquely carry a centromeric paralog, SMN2, nearly identical to SMN1. A single silent C-to-T difference in exon 7 does not change an amino acid but disrupts a splicing enhancer, so most SMN2 transcripts skip exon 7 and yield an unstable, truncated protein. Only ~10–15% of SMN2 output is full-length, functional SMN. Critically, SMN2 exists in variable copy number across individuals, and because each copy contributes a small trickle of working protein, SMN2 copy number is the major modifier of severity: more copies sum to more residual SMN, pushing motor neurons above their survival threshold and producing a milder phenotype. This biology is the linchpin of two of the three approved drugs — both nusinersen and risdiplam work by forcing SMN2 to include exon 7, converting the patient's own backup gene into a fuller source of functional SMN; gene therapy instead supplies a brand-new SMN1.

A useful organizing distinction separates the congenital myopathies from the muscular dystrophies, and it is fundamentally a distinction of mechanism visible down the microscope. In the dystrophies, the defect is in proteins that keep the fiber membrane structurally intact (dystrophin, the sarcoglycans, dysferlin), so the biopsy shows ongoing necrosis, regeneration, and fibro-fatty replacement — fibers are actively dying. In the congenital myopathies, the contractile machinery is mis-assembled but the fiber survives; the biopsy instead shows a named structural lesion (nemaline rods, central cores, abnormal nuclei) on a relatively non-dystrophic background. This is why the congenital myopathies tend to be static or only slowly progressive — the muscle is built wrong rather than breaking down — whereas the dystrophies relentlessly worsen.

Why the biopsy pattern points to the gene. The structural lesion is often a direct fingerprint of the culprit protein. Nemaline rods are aggregates of thin-filament (actin/tropomyosin/nebulin) proteins, so they implicate genes of the thin filament. Central cores are zones devoid of mitochondria and oxidative enzyme activity, reflecting disrupted calcium handling — which is why core disease centers on RYR1, the skeletal-muscle calcium-release channel, and why the same gene confers malignant hyperthermia susceptibility. Reading the biopsy therefore narrows the genetic search before a single gene is sequenced.

The major genetic muscular dystrophies beyond DMD/BMD include the limb-girdle muscular dystrophies (LGMD) — a large family in which different DAPC and membrane-repair proteins are lost, each producing the shared limb-girdle pattern from a different molecular cause — along with Emery-Dreifuss MD (nuclear-envelope proteins, with a dangerous cardiac-conduction emphasis) and facioscapulohumeral MD (FSHD) (an epigenetic derepression of the toxic DUX4 gene).

Charcot-Marie-Tooth disease (CMT) is the most common hereditary neuromuscular disorder (~1/2,500) and, with over 100 causative genes, also among the most genetically heterogeneous. The clinically decisive first cut, however, is not the gene but the nerve-conduction physiology, which sorts CMT into two mechanistic classes. Demyelinating CMT (CMT1) reflects defective myelin: conduction velocity is uniformly and markedly slowed because the insulation is faulty, even though axons are present. Axonal CMT (CMT2) reflects loss of the conducting wires themselves: velocity is near-normal but amplitudes are reduced. CMT1A illustrates the demyelinating mechanism elegantly — it is caused not by a coding mutation but by a duplication of the dosage-sensitive PMP22 myelin gene, so the disease is one of too much of a normal protein, a gene-dosage effect.

Why CMT is length-dependent. Whatever the molecular lesion, the longest axons fail first, because a peripheral motor neuron must maintain a process up to a meter long on transport machinery that any myelin or mitochondrial defect taxes most severely at its far end. This 'dying-back' produces the stereotyped distal-to-proximal march — foot drop, pes cavus, and hammertoes before the hands are involved — that unifies otherwise diverse genotypes.

Channelopathies — disease without degeneration. The hereditary channelopathies are a conceptually different category: the muscle is structurally normal, but a mutated ion channel makes the sarcolemma electrically unstable, producing episodic weakness (periodic paralysis) or delayed relaxation (myotonia) rather than fixed degeneration. The direction of the defect predicts the phenotype — chloride-channel loss removes the membrane's stabilizing 'brake' and causes myotonic over-excitability, whereas sodium- or calcium-channel dysfunction can paralyze the fiber during shifts in serum potassium. Together with the congenital myasthenic syndromes (inherited failures of NMJ transmission), they complete the spectrum of hereditary neuromuscular disease.